Michael Grosse to succeed Joachim Kreuzburg as Chief Executive Officer of Sartorius AG
Grosse to take over as Group CEO on July 1, 2025
The Supervisory Board of Sartorius AG appointed Dr. Michael Grosse Chief Executive Officer of Sartorius. He will take over this position on July 1, 2025, from Dr. Joachim Kreuzburg, who will continue to lead the company until that time. The appointment is the result of a selection process that started in the summer of 2024, after Kreuzburg had announced that, after more than two decades as CEO, he would not seek another renewal of his contract, which expires in November 2025.
The Chairman of the Supervisory Board, Dr. Lothar Kappich, commented: ”Joachim Kreuzburg's track record after 22 years at the helm of the company is unparalleled. With his dynamic entrepreneurial personality, he has transformed Sartorius into a life science tools company and led the company amongst the top of global players of this segment. During his term of office, Sartorius’ value increased tremendously while numerous new jobs were created. Following Mr. Kreuzburg’s early notice, we were able to organize a well-structured succession process which was successfully concluded with the appointment of Mr. Grosse. Michael Grosse has impressively demonstrated his operational and strategic skills across a range of industries and business models, and his openness, persistence and focus on results are an excellent match with the Sartorius culture. I am now very much looking forward to working together with Mr. Kreuzburg and our successful Executive Board for another six months, and then to welcoming Mr. Grosse to Sartorius next July.”
Joachim Kreuzburg said: ”Sartorius is a truly unique company with an outstanding positioning and a great team. In the coming months, we will work together with all our energy to ensure that the company continues to develop more innovatively, faster, and more profitably than the competition. I am pleased that in Mr. Grosse such a convincing personality has been found as my successor.”
Michael Grosse, designated Chief Executive Officer, said: ”Sartorius is a strongly positioned company in one of the most relevant industries of the future. The company has a powerful mission, and I look very much forward to contributing to the progress in the biopharma industry with this successful team in a few months’ time.“
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
